Press Releases

Archives: Search / 2020

2019201820172016201520142013201220112010200920082007

May 13, 2020
- Data highlighted shows continued progress on clinical trials for the KEYTRUDA plus LENVIMA combination across multiple tumor types, including a virtual oral presentation on the Phase 2 results of the metastatic clear cell renal cell carcinoma (mccRCC) cohort of a Phase 1b/2 study of KEYTRUDA plus LENVIMA

Eisai announced today the presentation of data and analyses across six cancer types at the American Society of Clinical Oncology's ASCO20 Virtual Scientific Program from May 29-31. Data from...

More
Mar 19, 2020

Eisai announced today that positive results from a Phase 2 study (Study 111/KEYNOTE-146) of lenvatinib (marketed as LENVIMA®), an orally available kinase inhibitor discovered by Eisai, in...

More
Feb 15, 2020
-- Results from a Phase 2 trial presented at ASCO GU 2020

Eisai presented today results from a Phase 2 trial assessing the efficacy and safety of lenvatinib (marketed as LENVIMA®) in combination with everolimus (LEN+EVE) in patients with unresectable...

More
Feb 13, 2020

Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ® (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S. This action is being...

More
Feb 10, 2020

Eisai announced today the presentation of three abstracts at the 2020 Genitourinary Cancers Symposium (#GU20) in San Francisco from February 13-15. New data to be presented on lenvatinib (marketed...

More
Feb 10, 2020
Fashion Show Highlights the #ThisIsMBC Beneath the Breast Campaign

Presenting sponsor Eisai Inc. and METAvivor announce today that they have joined forces with AnaOno Intimates and #Cancerland to fearlessly unite the breast cancer community and shine a spotlight...

More
Feb 3, 2020
Executive Appointments:

As Eisai Inc. continues to bring innovative medicines and dynamic solutions to the marketplace, the company announces today the expansion of its leadership team to include two key appointments in...

More
Jan 22, 2020

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it has been selected as the highest rated company “A” in the Climate Change Report 2019 issued by the...

More
Jan 21, 2020

Eisai announced today the presentation of three abstracts at the 2020 Gastrointestinal Cancers Symposium (#GI20) in San Francisco from January 23-25. New data to be presented on lenvatinib...

More
Dec 27, 2019

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that JAMA Network Open (www.jamanetwork.com) published results of SUNRISE 1 (Study 304), a pivotal Phase 3...

More
Dec 23, 2019
Approval Based on Robust Clinical Development Program That Included Two Pivotal Trials of Nearly 2,000 Patients

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the U.S. Food and Drug Administration (FDA) approved DAYVIGO™ (lemborexant) 5 mg and 10 mg for the treatment of...

More
Dec 10, 2019

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced that new data findings for two investigational assets in its robust dementia pipeline were presented at the 12th...

More
Dec 10, 2019

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN®) will be presented during the 42nd San Antonio...

More
Dec 9, 2019
Eisai presents key data at the 2019 American Epilepsy Society Annual Meeting

Eisai Inc. presented the latest healthcare economic (HCEI) data for FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore, Maryland. Cumulatively, more than...

More
Dec 9, 2019
Key data results:

Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore....

More
Dec 5, 2019
Latest Initiative of #ThisIsMBC to be Unveiled at the 2019 San Antonio Breast Cancer Symposium

Eisai Inc. and METAvivor today announced the launch of Beneath the Breast, a new initiative of the #ThisIsMBC campaign. Beneath the Breast spotlights imagery of eight people living with metastatic...

More
Dec 2, 2019
New Data from Eisai's Robust Dementia Pipeline Will Be Shared, Including Analyses of Investigational Alzheimer's Disease Compounds and Diagnostic Methods

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new data from the company's rich dementia pipeline, including BAN2401, lemborexant and diagnostics methods, will...

More
Nov 25, 2019
Key presentations include:

Eisai Inc. today will present FYCOMPA® (perampanel) CIII data on convulsive seizure freedom and additional analyses of FYCOMPA at the upcoming American Epilepsy Society Annual Meeting taking...

More
Nov 12, 2019
Ella the Jellyfish Brings Comfort and Support to Children with LGS as well as their Families and Caregivers

Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., today announced the launch of Ella the Jellyfish, the first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome (LGS). The...

More
Oct 22, 2019
New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints

Cambridge, Mass. and Tokyo, Japan – October 22, 2019 – Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that, after consulting with the U.S. Food and Drug...

More